Withdrawal of a low dose (5 mg) of corticosteroids in systemic lupus in remission for more than a year is at risk of relapse – the corticoliup trial

Micheline Pha,1 Alexis Mathian,2,7 Julien Harache,3,8 Miguel Hié1,7 Fleur Cohen,1 Du Boulin-Le Th Huong,1 Marc Pineton de Chambrun,1 Patrick Cherini,3–5 Catherine Duyckaerts1,2,7,8,9 Hélène Safro,1,8,9 Assistance Publique-Hôpitaux de Paris (APHP), Rare Diseases Referral Center for Systemic Lupus Erythematosus, Antiphospholipid Antibody Syndrome and Rare Autoimmune Diseases, Service de Médecine Interne 2, Paris, France, Sorbonne Université, Centre d’Immunologie et des Maladies Infectieuses (CIM), INSERM U1135, Paris, France, Centre Hospitalier Universitaire de Dijon, Hôpital Français Mittrier, Service de Médecine Interne et Maladies Métaboliques, Dijon, France, Centre Hospitalier Universitaire de Dijon, Hôpital François Mittrier, Centre d’Investigation Clinique, INSERM CIC 1432, Dijon, France

Background: Glucocorticoids (GCs) are a mainstay of treatment for patients with SLE but are associated with significant adverse effects. Some SLE patients are maintained for a long-term under a low dose of prednisone to prevent relapse. There is no scientific data to sustain this therapeutic strategy.

Objectives: We hypothesized that maintaining a daily dose of 5 mg prednisone in patients with an inactive SLE for at least a year would prevent the risk of relapse.

Methods: The CORTICOLUP study (NCT02558517) was a prospective randomized, open-label, controlled, monocentric study that sought to compare maintenance vs withdrawing of low-dose of prednisone (5mg) to reduce SLE flares, conducted from January 2014 to March 2017. Inclusion criteria were SLE patients who during the year preceding the inclusion had 1/4 inactive SLE defined by a SLEDAI-2K score ≤4, a BILAG-2004 index C, D or E in all systems and a PGA = 0 and 2/4 stable SLE treatment including prednisone 5 mg daily.

There were significantly more flares in the withdrawal group compared to the maintenance group (17 flares versus 4, p = 0.0034 using the Fisher’s exact test). Mild or moderate flares were more frequent in the withdrawal group compared to the maintenance group (12 vs 3, p = 0.028). The occurrence of severe flare was not significantly different between the two groups (5 vs 1, p = 0.208). More than two-thirds of the flares in the withdrawal group occurred within the first six months. Within the withdrawal group, using forest plot analysis, no significant association was found between the occurrence of a flare and age, sex, duration of SLE, duration of SLE remission, duration of GCs treatment, immunosuppressants and serological SLE activity at randomization. Four patients in the withdrawal group and none in the maintenance group experienced damage: 2 osteoporosis bone fractures, 1 hydroxychloroquine retinopathy and 1 cataract.

Conclusion: Withdrawal of low dose of steroids in patients with inactive SLE and stable therapeutic regimen for more than a year is associated with a high risk of relapse.

Disclosure of Interests: None declared

that reported the incidence of sustained amenorrhoea (defined as at least 12 months of amenorrhoea) during i.v.CYC treatment in patients with ARD; and those that assessed the incidence of sustained amenorrhoea in patients receiving GnRHa and i.v.CYC, compared to controls receiving i.v.CYC alone.

**Results:** 1099 articles were identified and their titles and abstracts screened, following which 81 papers were selected for full text review. 31 studies were then identified that addressed the risk of sustained amenorrhoea with i.v.CYC in n=1382 patients with ARD. The majority of these patients had systemic lupus erythematosus (1326 out of 1382 patients, 96.0%). The mean age was 24.9 years (range 13-36.1 years). Sustained amenorrhoea occurred in 269 patients (19.5%, range 0-54% depending on age and cumulative cyclophosphamide dose). The rate of sustained amenorrhoea significantly positively correlated with increasing cumulative cyclophosphamide dose, and occurred in patients with a mean age ranging from 13-36.1 years at mean cumulative doses ranging from 1-20.1 g. Further, 3 out of 1382 ARD patients given i.v.CYC +/- GnRHa, including 56 patients (mean age range 23.9-29.6 years) receiving GnRHa and i.v.CYC, and 37 controls (mean age range 25-29.4 years) given i.v.CYC only. Sustained amenorrhoea occurred in 2/56 (3.6%) patients treated with GnRHa, compared to 15/37 (40.5%) of controls. The pooled odds ratio of sustained amenorrhoea with GnRHa and i.v.CYC compared to i.v.CYC alone was 0.0543 (95%CI 0.0115-0.2576, p<0.0002). The number needed to treat was 2.7 (95%CI 2.0-4.4) and the absolute risk reduction was 97.0% (95%CI 35.6-38.4%).

**Conclusion:** Although the risk of POI with i.v.CYC was associated with increasing age, it was observed across all age groups and from cumulative doses of 1g or more. GnRHa markedly reduced this risk in ARD, and therefore should be considered for concomitant use with i.v.CYC in all women of child-bearing age with ARD.

**REFERENCES:**


**Acknowledgement:** Arthritis Australia

**Disclosure of Interests:** Shi-Nan Luong: None declared, Anthony Isaacs: None declared, Fang En Sin : None declared, Ian Giles Consultant for: UCB, Speakers bureau: UCB

**DOI:** 10.1136/annrheumdis-2019-eular.2411

---

**OP0045**

**ABATACEPT TREATMENT OF PATIENTS WITH EARLY ACTIVE PRIMARY SJÖGREN’S SYNDROME – A RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED PHASEFRED K.L. SPIJKERVELTY. K. ONNO TENGE-J. ARENDS III-STUDY (ASAP-III)**

Jolien F. van Nimwegen1, Greteet S. van Zuiden1, Suzanne Arends1.

**Background:** Systemic treatment is not yet available for primary Sjögren syndrome (pSS). Abatacept (CTLA-4-Ig) targets the CD80/CD86:CD28 stimulatory pathway required for full T-cell activation and T-cell dependent activation of B-cells. IV abatacept was shown to be safe, well tolerated, and to decrease disease activity in an open-label study of 15 pSS patients.

**Objectives:** To assess the efficacy and safety of subcutaneous (SC) abatacept vs. placebo in patients with early active pSS.

**Methods:** The Abatacept Sjögren Active Patients phase III (ASAP-III) study is a monocenter, investigator-initiated, double-blind, placebo-controlled trial (NCT02067910). ASAP-III included 80 adult patients with biopsy-proven pSS, fulfilling the AECG and ACR/EULAR criteria, with a disease duration of ≥7 years and moderate to high EULAR Sjögren Syndrome Disease Activity score (ESSDAI) ≥5. Patients were randomized in a 1:1 ratio to receive weekly SC abatacept (125 mg) or placebo for 24 weeks (figure 1). After the double-blind phase, all patients were treated with abatacept in a 24-week open label phase. Concomitant use of other DMARDs was not permitted, with the exception of a stable dose of prednisone (≤10mg). Rescue therapy with prednisone or cyclophosphamide was permitted after week 12. Participants visited our pSS tertiary referral center nine times, to be evaluated by a multidisciplinary team of rheumatologists, ophthalmologists, and oral and maxillofacial surgeons.

The primary endpoint was ESSDAI at 24 weeks. Secondary outcomes over 24 and 48 weeks include clinical, patient reported, functional, histological, laboratory, ultrasound, and microbiome parameters, and the occurrence of (serious) adverse events and treatment discontinuation.

**Results:** Baseline characteristics of participants are shown in table 1. Database lock for the blinded stage is planned in March 2019. Subsequently, the first intention-to-treat analyses will be performed, focusing on the ESSDAI and EULAR Sjögren Syndrome Patient Reported Index (ESSPRI), quality of life (EQ-5D), unstimulated and stimulated whole salivary flow (UWS, WSS), Schirmer test, Ocular Staining Score (OSS), serological parameters (RF, IgG), and safety parameters.

**Conclusion:** The ASAP-III trial was designed to assess the clinical efficacy and safety of SC abatacept in pSS patients with short disease duration and active disease. The 24-week results will be available during the EULAR congress 2019.

**Figure 1.** Design of the ASAPIII study.

**Disclosure of Interests:** [Reference]

---

**Table 1:** Baseline characteristics of participants (n=80)

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>mean±SD 48.8±15.6</td>
</tr>
<tr>
<td>Female (% )</td>
<td>74 (93)</td>
</tr>
<tr>
<td>Disease duration (years), median (IQR)</td>
<td>2.0 (1.0–4.0)</td>
</tr>
<tr>
<td>Anti-Ro/SSA, n (%)</td>
<td>71 (89)</td>
</tr>
<tr>
<td>Previous use of DMARDS, n (%)</td>
<td>34 (42.5)</td>
</tr>
<tr>
<td>Use of prednisone, n (%)</td>
<td>1 (2)</td>
</tr>
<tr>
<td>ESSDAI, median (IQR)</td>
<td>13 (9–17)</td>
</tr>
<tr>
<td>ESSPRI, median (IQR)</td>
<td>6.7 (1–6.6)</td>
</tr>
<tr>
<td>EQ-5D index, median (IQR)</td>
<td>0.71 (0.57–0.84)</td>
</tr>
<tr>
<td>UWS (mL/min), median (IQR)</td>
<td>0.05 (0.01–0.13)</td>
</tr>
<tr>
<td>SWS (mL/min), median (IQR)</td>
<td>0.16 (0.04–0.30)</td>
</tr>
<tr>
<td>OSS*, median (IQR)</td>
<td>4.5±3.4</td>
</tr>
<tr>
<td>Schirmer* (mm/5 min), median (IQR)</td>
<td>3 (0–10)</td>
</tr>
<tr>
<td>IgG (gL), median (IQR)</td>
<td>18.2 (14.4-25.9)</td>
</tr>
<tr>
<td>RF (IU/mL), median (IQR)</td>
<td>28 (5–71)</td>
</tr>
</tbody>
</table>

* Average of left and right eye.

**Disclosures of Interests:** Jolien F. van Nimwegen Speakers bureau: Bristol-Myers Squibb, Greteet S. van Zuiden Speakers bureau: Roche, Suzanne Arends Grant/research support from: Grant/research support from: Pfizer, Esther Mossel: None declared, Robin F. Wijnsma: None declared, Alja J. Stel: None declared, Konstantina Delli: None declared, Bert van der Vegt: None declared, Erolin A. Haacke: None declared, Lisette Olie: None declared, Leonie I. Los: None declared, Janita Bulthuis-Kuiper: None declared, Gwynn M. Verstappen: None declared, Sarah A. Pringle: None declared, Fred K.L. Spijkervet: None declared, Frans G.M. Kroese: None declared, Frans G.M. Kroese Speakers bureau: Roche, Bristol-Myers Squibb: Consultant for: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb: Roche, Janssen-Cilag: Arjan Vissink: None declared, Hendrika Bootstra: None declared, Konstantina Delli: None declared, Bert van der Vegt: None declared, Erolin A. Haacke: None declared, Lisette Olie: None declared, Leonie I. Los: None declared, Janita Bulthuis-Kuiper: None declared, Gwynn M. Verstappen: None declared, Sarah A. Pringle: None declared, Fred K.L. Spijkervet: None declared, Frans G.M. Kroese Grant/research support from: Unrestricted grant from Bristol-Myers Squibb, Consultant for: Bristol-Myers Squibb, Speakers bureau: Bristol-Myers Squibb, Roche, Janssen-Cilag: Arjan Vissink: None declared, Hendrika Bootstra Grant/research support from: Unrestricted grants from Bristol-Myers Squibb and Roche, Consultant for: Roche, Bristol-Myers Squibb, Novartis, Medimmune, Union Chimique Belge, Speakers bureau: Bristol-Myers Squibb, Novartis

**DOI:** 10.1136/annrheumdis-2019-eular.970

---

**OP0046**

**MULTICENTRIC STUDY COMPARING CYCLOSPORINE, MYCOPHENOLATE MOFETIL AND AZATHIOPRINE IN THE MAINTENANCE THERAPY OF LUPUS NEPHRITIS: 10 YEARS FOLLOW UP**

Lorena Maria Argolini1,2, Elena Elefante3, Francesca Saccon4, Valentina Bindia5, Maria Gerosa1,2, Luigi Sinigaglia3, Piergiorgio Messa3, Andrea Doria3, Marta Mosca2, Gabriella Moroni3, 1University of Milan, Clinical Sciences and Community Health, Milan, Italy; 2ASST Istituto Gaetano Pini – CTO, Clinical Rheumatology, Milan, Italy; 3Rheumatology Unit, University of Pisa, Clinical and Experimental Medicine, Pisa, Italy; 4University of Padua, Rheumatology, Padova, Italy; 5Fondazione Ca’ Granda IRCCS Ospedale Maggiore Policlinico Milano, Nephrology, Milan, Italy

**Background:** The most effective drug for the maintenance therapy of severe forms of lupus nephritis (LN) is still a matter of debate.

**Disclosure of Interests:** [Reference]